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Background: Evidence regarding the utility of endobronchial ultra-
sound-guided transbronchial needle aspiration (EBUS-TBNA) in the
assessment of isolated mediastinal lymphadenopathy (IMLN) is
evolving. Its diagnostic accuracy in the evaluation of suspected
lymphoma remains uncertain.
Methods: We reviewed a prospectively recorded database of con-
secutive patients with suspected lymphoma who underwent EBUS-
TBNA to evaluate IMLN. Patients in whom EBUS-TBNA was
nondiagnostic subsequently underwent surgical biopsy or a mini-
mum of 6 months radiologic surveillance.
Results: Ninety-eight patients underwent EBUS-TBNA for evalu-
ation of IMLN. Clinicoradiologic features suggested sarcoidosis as
the likely diagnosis in 43 patients. In the remaining 55 patients,
EBUS-TBNA achieved definitive diagnosis in 42 patients (76%;
95% confidence interval [CI] 55–90). Lymphoma was ultimately
diagnosed in 21 of 55 patients (38%). EBUS-TBNA demonstrated
lymphoma in 16 (76%) patients; however, four patients required
further surgical biopsy to completely characterize lymphoma sub-
types. Surgical biopsy was required to diagnose specific lymphoma
subtypes not readily amenable to diagnosis with low volume spec-
imens. Sensitivity and specificity for definitive diagnosis of lym-
phoma were 57% (95% CI 37–76) and 100% (95% CI 91–100),
respectively.
Conclusions: Although the diagnostic accuracy of EBUS-TBNA for
lymphoma is lower than that for the lung cancer staging, the
procedure is an appropriate investigative technique for the patients
with IMLN because of the low incidence of lymphoma in this
population, and the significant proportion of such patients (76%) in
whom surgical biopsy is obviated.
Key Words: Bronchoscopy, Cytology, Lymphadenopathy, Lym-
phoma, Small volume specimens.
(J Thorac Oncol. 2010;5: 804–809)
Endobronchial ultrasound-guided transbronchial needle as-piration (EBUS-TBNA) was first developed to allow min-
imally invasive mediastinal staging of patients with non-
small cell lung cancer (NSCLC), and there is now extensive
literature confirming both the diagnostic accuracy and the
safety of the procedure for this indication.1,2 Diagnostic
sensitivity in mediastinal staging of NSCLC is at least equiv-
alent to mediastinoscopy and significantly higher for certain
lymph node (LN) stations.3 Meta-analyses estimate the diag-
nostic sensitivity to be 0.92.1,2 In addition, the morbidity and
mortality of EBUS-TBNA (0.15% and 0%, respectively)
compares favorably with mediastinoscopy (2–5% and 0.2%,
respectively).4–6
Evidence regarding the utility of EBUS-TBNA in the
assessment of mediastinal lymphadenopathy in other condi-
tions is evolving. Several authors have described the high
diagnostic yield of EBUS-TBNA in sarcoidosis,7–10 and small
case series indicate that EBUS-TBNA is also useful in the
evaluation of suspected tuberculosis.11,12 To date, there is
only a single retrospective study examining the performance
of EBUS-TBNA in the diagnosis of lymphoma.13
There is considerable controversy regarding the role of
small volume diagnostic specimens in lymphoma, with stud-
ies suggesting a high rate of discordance between cytologic
and histologic specimens in patients.14 As treatment regimens
for both Hodgkin and non-Hodgkin lymphoma (NHL) gen-
erally dependent on the specific subtype and histologic grade,
many centers are reluctant to rely on small volume diagnostic
specimens. The ability of the 22-gauge EBUS-TBNA needle
currently in use to provide accurate diagnostic information
has yet to be determined. In a recent meta-analysis, it was
concluded that there was insufficient evidence to recommend
EBUS-TBNA for the evaluation of suspected lymphoma and
that further studies investigating the performance of this
technique for the evaluation of lymphoma are required.2
In our centers, we have performed EBUS-TBNA for
initial evaluation of mediastinal lymphadenopathy when lym-
phoma is a suspected diagnosis given the potential benefit of
establishing this diagnosis using a minimally invasive tech-
nique. This is weighed against the possibility that a second
invasive surgical procedure may be required to definitively
establish the diagnosis. In this report, we present our experi-
ence of EBUS-TBNA for the diagnosis of lymphoma.
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METHODS
Patients
From the time of inception of EBUS-TBNA at our two
tertiary referral centers, we have prospectively recorded de-
mographic and detailed clinical information for all completed
procedures. Clinical data include principal indication for
performance of EBUS-TBNA, any previous history of carci-
noma or lymphoma, pattern of lymphadenopathy, suspected
preprocedure diagnosis, and final pathologic diagnosis. We
have previously noted that the patients with isolated (i.e., in
the absence of a parenchymal lung lesion) mediastinal lymph-
adenopathy (IMLN) or hilar lymphadenopathy undergoing
EBUS-TBNA may be separated into two groups15—patients
with typical clinicoradiologic features of sarcoidosis16 and
patients in whom sarcoidosis is unlikely to be the cause of
IMLN. Lymphoma is extremely rare in the first group4;
however, it should be suspected as a possible cause of
lymphadenopathy in the latter group.
We aimed to determine the diagnostic sensitivity and
specificity of EBUS-TBNA in the evaluation of suspected
lymphoma in the patients with IMLN. Therefore, we per-
formed a retrospective review of our prospectively recorded
database to identify all patients undergoing EBUS-TBNA for
evaluation of IMLN. Those with typical clinicoradiologic
features of sarcoidosis were excluded from the study.
Performance of EBUS-TBNA
EBUS-TBNA was performed by consultant respiratory
physicians experienced in performance of EBUS-TBNA (D.P.S.
and M.C.). A dedicated linear array bronchoscope (BF-
UC180F-OL8, Olympus, Tokyo, Japan) was used to visualize
pathologic LNs, as directed by CT chest findings, before per-
formance of EBUS-TBNA using a 22-gauge needle (NA-
201SX-4022, Olympus, Tokyo, Japan). A minimum of three
needle passes were performed with initial material transferred to
the slides for rapid on-site cytologic evaluation and subsequent
material placed in formalin solution to allow the preparation of
a cell block for histologic evaluation and immunocytochemical
analysis. Immunohistochemical analyses were performed at the
discretion of the reporting pathologist.
A diagnosis was considered a true positive diagnosis if
the reviewing pathologist was able to make a definitive
diagnosis on the basis of the specimen obtained at EBUS-
TBNA and the treating clinician felt no further LN specimen
was required before commencement of therapy. A true neg-
ative diagnosis was represented by any of EBUS-TBNA
specimen negative for lymphoma with an alternate definitive
diagnosis established, or subsequent surgical biopsy confirm-
ing the absence of lymphoma, or either stability or regression
of lymphadenopathy during follow-up of a minimum 6
months duration.
Statistical Methods
Summary statistics were used to report the performance
characteristics of EBUS-TBNA. Sensitivity and specificity
were calculated for performance of this technique for the
diagnosis of lymphoma. Statistical analysis was performed
using GraphPad Instat 3 for Macintosh (GraphPad Software,
La Jolla, CA). Institutional review board approval was
granted for the performance of this study.
RESULTS
Between October 1, 2008 and September 30, 2009, 55
patients underwent EBUS-TBNA for the evaluation of
IMLN. Eight patients had a previous history of carcinoma or
sarcoma, and eight patients had a previous history of lym-
phoma. During this period, surgical biopsies to evaluate
IMLN were performed only if EBUS-TBNA was not diag-
nostic. No complications from the procedure were noted
among our cohort.
Overall, 48 of 55 (87%) procedures yielded adequate
tissue for cytopathologic evaluation, and definitive diagnosis
was achieved for 42 (76%). Diagnoses resulting from EBUS-
TBNA are recorded in Table 1. Overall, lymphoma was
found to be the cause of IMLN in 21 patients (38%). Only
two of these patients had a previous history of lymphoma.
EBUS-TBNA provided tissue enabling demonstration of
lymphoma in 16 patients (76%), and 12 of these patients
required no further LN tissue to guide management (Figure
1A). Three patients in whom EBUS-TBNA demonstrated
lymphoma required further surgical biopsy to subtype their
disease sufficiently to guide subsequent treatment (Figure
1B), and one patient underwent confirmatory biopsy to enable
subclassification of Hodgkin lymphoma (HL). A further four
patients with nondiagnostic EBUS-TBNA required a surgical
TABLE 1. Results Demonstrated by EBUS-TBNA
Lymphoma 16
Diffuse large B-cell lymphoma 5
Hodgkin lymphoma (classic) 2
Small lymphocytic lymphoma 2
B-cell lymphoma NOS 2
Large cell lymphoma 1
T-cell lymphoma 1
Lymphoma NOS 1
Anaplastic large cell lymphoma 1
Lymphomatous cells, suggestive of HL 1
Metastatic carcinoma 6
Breast carcinoma 3
Renal cell carcinoma 2
Melanoma 1
NSCLC 5
Small cell lung cancer 3
Metastatic sarcoma 3
Osteosarcoma 2
Ewings sarcoma 1
Amyloid tumour 1
Normal lymphoid tissue 8
Sarcoidal granulomas 3
Mycobacterium tuberculosis 2
Bronchogenic cyst 1
Inadequate specimen 7
NOS, not otherwise specified; NSCLC, non-small cell lung carcinoma; HL,
Hodgkin lymphoma; EBUS-TBNA, endobronchial ultrasound-guided transbronchial
needle aspiration.
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procedure to diagnose lymphoma, and one patient, with a
previous history of lymphoma, refused further surgical biop-
sies after a nondiagnostic EBUS-TBNA and has been as-
sumed to have had a false negative biopsy for the purpose of
this analysis. Figure 2 records all patients with lymphoma
according to whether EBUS-TBNA was able to demonstrate
a definitive diagnosis.
Of the patients in whom EBUS-TBNA failed to obtain
adequate tissue for cytopathologic evaluation, three were
diagnosed with lymphoma after surgical biopsy. A further
two patients underwent surgical biopsy to demonstrate benign
causes for IMLN, and two patients remain well during ongo-
ing clinical and radiologic follow-up. Lymphoma was the
final diagnosis in two of eight patients in whom EBUS-
TBNA demonstrated normal lymphocytes. The remaining six
patients have undergone clinical and radiologic follow-up for
a minimum of 6 months, and no alternate diagnoses has been
made for these patients.
The diagnostic sensitivity for detection of lymphoma
by EBUS-TBNA was 76% (95% confidence interval [CI]
55–90). However, in four patients in whom EBUS-TBNA
indicated a diagnosis of lymphoma, further surgical biopsy
was required to definitively confirm the diagnosis, and thus,
we believe the diagnostic sensitivity is more accurately re-
ported as 57% (95% CI 37–76). Specificity and negative
predictive value (NPV) for the detection of lymphoma were
100% (95% CI 91–100) and 87% (95% CI 72–95), respec-
tively.
DISCUSSION
Our findings demonstrate that EBUS-TBNA is a safe
method for the evaluation of suspected lymphoma. Although
lymphoma was the cause of IMLN in only 38% of patients,
definitive diagnosis was achieved by EBUS-TBNA in 76% of
all patients with IMLN, allowing all these patients to avoid
invasive surgical biopsy, and the attendant risks. Sensitivity
of EBUS-TBNA for the detection of lymphoma was 76%,
and the sensitivity for the definitive diagnosis of lymphoma
was 57%. Although sensitivity is reduced, compared with
sensitivity of EBUS-TBNA for the detection of NSCLC
metastases,1,2 we still noted a NPV of 87%.
FIGURE 1. A, EBUS-TBNA specimen demonstrating a uniform
population of small lymphocytes. Immunohistochemical stain-
ing was positive for CD 20 (pictured), CD 5, and CD23 con-
firming small lymphocytic lymphoma. B, EBUS-TBNA specimen
demonstrating malignant cells in a background of lymphoid
cells. Immunohistochemistry showed positive staining with CD
30 (pictured) and negative staining for epithelial markers.
EBUS-TBNA specimens suggested anaplastic large cell lym-
phoma. Surgical biopsy confirmed the presence of anaplastic
large cell lymphoma. EBUS-TBNA, endobronchial ultrasound-
guided transbronchial needle aspiration.
FIGURE 2. Flow diagram illustrating the method by which
diagnosis was achieved in all patients ultimately diagnosed
with lymphoma. Final diagnoses are grouped according to
the utility of EBUS-TBNA for each patient. EBUS-TBNA, endo-
bronchial ultrasound-guided transbronchial needle aspira-
tion; IMLN, isolated mediastinal lymphadenopathy; HL,
Hodgkin lymphoma; LN, lymph node.
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Patients with lymphoma in whom definitive diagnosis
was not demonstrated by EBUS-TBNA seemed to have
particular disease subtypes that may explain the difficulties in
achieving this. Our findings reflect those of a previous study
demonstrating that specific subtypes of lymphoma, such as
small lymphocytic lymphoma, are relatively readily diag-
nosed on low-volume tissue specimens, whereas others, such
as marginal zone and follicular lymphomas, are difficult to
definitively diagnose on low volume specimens.17 Patients in
our study required subsequent surgical procedures to diag-
nose hypocellular variants of HL, marginal zone lymphoma,
or to fully classify demonstrated B-cell NHL.
The diagnosis of lymphoma requires the evaluation of
individual cell morphology (cytology), immunophenotype,
and the overall architecture of the malignant tissue (histology).18
Samples may also be sent for molecular analysis (to identify
certain oncogenes) and immunophenotyping (to characterize
the malignant lymphocyte, determine the presence of a ma-
lignant clone and subclassify NHL). Management of NHL
may range from observation alone (small lymphocytic lym-
phoma and some follicular lymphoma) to conventional che-
motherapy (for example, follicular or marginal zone lym-
phoma) or even autologous stem-cell transplantation (mantle
cell lymphoma). Thus, obtaining sufficient tissue to facilitate
an accurate diagnosis of a B-cell lymphoma subtype is of
great importance to the patient and clinician.
Diagnosis of HL by cytologic specimens poses unique
challenges to the pathologist, as cytologic samples are often
hypocellular (especially in nodular sclerosising disease).
There is often a marked paucity of Reed-Sternberg cells in
needle aspirates, and the variants are often present in a
background of reactive cells. False negative results may arise
if only reactive cells are aspirated by TBNA.19 Finally,
evaluation of the overall background architecture is important
in the diagnosis of HL.20,21 The recently developed 21-gauge
EBUS-TBNA may overcome these limitations to the use of
EBUS-TBNA in the diagnosis of HL, and this should be the
subject of future studies.
There are recognized situations when EBUS-TBNA
may be preferred, because the risks of surgical mediastinos-
copy are greater than in published series, for example, supe-
rior vena caval obstruction or mediastinal collateral vessel
formation (Figure 3). Another potential application of EBUS-
TBNA is in the assessment of patients with relapsed lym-
phoma. It is recognized that repeat mediastinoscopy or me-
diastinoscopy after mediastinal radiotherapy is associated
with reduced sensitivity and increased rate of major compli-
cations.22–24 In this situation, EBUS-TBNA offers a safer and
effective alternative to the more invasive mediastinoscopy.
Previous studies have emphasized that low-volume
tissue samples may avoid the need for surgical diagnosis in
lymphoma.25–27 Our results suggest the use of EBUS-TBNA
inpatients with undifferentiated lymphadenopathy when lym-
phoma is a suspected diagnosis is reasonable, despite the
necessity to proceed to a surgical diagnosis in a proportion of
patients. It is likely that EBUS-TBNA may avoid both the
morbidity and the financial costs associated with more inva-
sive surgical procedures although it should be undertaken
with the patient’s understanding that further morphologic
characterization of their disease by invasive surgical biopsy
may be required.
It is not possible to determine a priori if patients will
have a neoplasm not amenable to diagnosis by EBUS-TBNA
and whether a surgical biopsy will, therefore, ultimately be
required. Our experience indicates that EBUS-TBNA may
obviate surgical biopsy in a larger majority of patients with
suspected lymphoma, on the basis of IMLN (76%), as only a
minority of such patients will ultimately be demonstrated to
have lymphoma (38%).
FIGURE 3. A, Axial contrast-enhanced computed tomogra-
phy chest image from patient with clinical superior vena
cava (SVC) obstruction demonstrating prominent right para-
tracheal lymphadenopathy causing significant narrowing of
the SVC. Large collateral vessels in the right paratracheal re-
gion may be seen posterior to the narrowed SVC (arrow). B,
Endobronchial ultrasound image of right paratracheal region
of patient in (A). Doppler mode demonstrates large vessels
within a poorly defined lymph node mass (arrowheads).
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The only other published analysis of the performance of
EBUS-TBNA, by Kennedy et al.,13 reported a diagnostic
sensitivity of 90.0% in the evaluation of lymphoma, signifi-
cantly higher than our observed sensitivity. On closer exam-
ination, however, two patients in their cohort required surgi-
cal biopsy to subclassify their lymphoma. We believe that the
goal of EBUS-TBNA in these patients is to obviate invasive
surgical biopsy, and if mediastinoscopy is required to provide
further pathologic information to guide definitive therapy,
then this goal has not been achieved. Based on the criteria
applied to our series, the diagnostic sensitivity of EBUS-
TBNA in the study by Kennedy et al. would be 72.7% (8 of
11 patients), more comparable to our experience. The cohort
described by Kennedy et al. comprised patients predomi-
nantly with either HL or small lymphocytic lymphoma, two
subtypes more easily diagnosed on low-volume specimens,13
which provides another possible explanation for the higher
observed sensitivity in their report. Consistent with this
observation, four patients among our cohort in whom EBUS-
TBNA was not diagnostic had hypocellular subtypes of
lymphoma (sclerosing HL and marginal zone lymphoma),
and three required surgical biopsy to demonstrate tumor
architecture after demonstration of B-cell lymphomas by
EBUS-TBNA.
In addition, over half of the cohort described by
Kennedy et al. had a previous history of lymphoma. In
contrast, just two patients diagnosed with lymphoma in our
cohort had a previous disease history. The need for specific
subtyping may not be as important in patients with a past
history of lymphoma, because demonstration of a malignant
clone of lymphocytes may be adequate to guide management
in these patients. Finally, unlike Kennedy et al., we have
excluded patients with probable sarcoidosis from our analy-
sis. The rates of alternate diagnoses to sarcoidosis (such as
lymphoma) in those with typical clinicoradiologic features
have been reported as 0.05%4; therefore, it seems appro-
priate to remove such patients from calculations when assess-
ing the diagnostic accuracy of EBUS-TBNA in the evaluation
of suspected lymphoma. Exclusion of sarcoid cases from the
cohort reported by Kennedy et al. leaves a NPV of 83%,
rather than the reported 92.9%.
Strengths and Limitations
Our series is the largest report describing the use of
EBUS-TBNA in the evaluation of suspected lymphoma. Our
cohort consists of a wide variety of lymphoma subtypes and
excludes patients with likely sarcoidosis, which provides a
more accurate representation of NPV of the procedure.
We did not routinely use flow cytometry in the evalu-
ation of specimens; however, immunocytochemistry was per-
formed as required on diagnostic specimens, enabling the
identification of the diagnostic immunophenotype. Neverthe-
less, we were able to establish a definitive diagnosis in at least
57% of patients with lymphoma using immunocytochemistry
and morphology alone. False negative results for flow cytom-
etry are highest for B-cell lymphomas,28 and the exact group
in whom morphologic or architectural interpretation require-
ments makes EBUS-TBNA of potentially limited utility.
Fortunately, low-volume specimens may be more amenable
for other studies, such as fluorescent in situ hybridization for
the detection of cytogenetic rearrangements.29
Finally, the role of an experienced pathologist with an
interest in hematopathology and expertise in cytologic eval-
uation of these specimens cannot be underestimated. We
believe that the utility of EBUS-TBNA depends strongly on
the ability of the reviewing pathologist to interpret small
volume specimens. Institutions without such expertise should
not expect to be able to replicate our findings or those of
Kennedy et al. Conversely, diagnostic sensitivity may im-
prove further in future as pathologists gain greater experience
in interpreting specimens obtained by EBUS-TBNA.
CONCLUSION
In conclusion, our findings indicate that EBUS-TBNA
is a safe and effective procedure for the assessment of
patients with mediastinal lymphadenopathy because of sus-
pected lymphoma. The diagnostic sensitivity for the evalua-
tion of lymphoma is lower than that for lung cancer staging,
largely because of the difficulties of confirming the diagnosis
of lymphoma on a small volume specimen in some disease
subtypes, such as marginal zone lymphomas, or hypocellular
variants of Hodgkin disease. EBUS-TBNA may still be
considered as the initial investigative technique of suspected
lymphoma as it may obviate the need for more invasive
surgical biopsy in the majority of such patients.
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